Compare VVX & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVX | MESO |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2014 | N/A |
| Metric | VVX | MESO |
|---|---|---|
| Price | $69.05 | $14.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $69.50 | N/A |
| AVG Volume (30 Days) | ★ 526.2K | 263.1K |
| Earning Date | 05-04-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 126.85 | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $4,480,038,000.00 | N/A |
| Revenue This Year | $7.21 | $644.56 |
| Revenue Next Year | $5.52 | $38.70 |
| P/E Ratio | $27.78 | ★ N/A |
| Revenue Growth | ★ 3.65 | N/A |
| 52 Week Low | $42.09 | $9.61 |
| 52 Week High | $75.00 | $21.50 |
| Indicator | VVX | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 39.34 |
| Support Level | $52.66 | $14.53 |
| Resistance Level | $71.40 | $16.33 |
| Average True Range (ATR) | 2.29 | 0.45 |
| MACD | -0.46 | -0.01 |
| Stochastic Oscillator | 30.51 | 17.54 |
V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.